Venmax Drugs & Pharmaceuticals Inc Stock Price Today (NSE: VENMAX)
Fundamental Score
Venmax Drugs & Pharmaceuticals Inc Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Venmax Drugs & Pharmaceuticals Inc share price today is ₹21.18, down 7.67% on NSE/BSE as of 22 June 2026. Venmax Drugs & Pharmaceuticals Inc (VENMAX) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹15.62 (Cr). The 52-week high for VENMAX share price is ₹36.96 and the 52-week low is ₹19.01. At a P/E ratio of 45.94x, VENMAX is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 6.38% and a debt-to-equity ratio of 0.36.
Venmax Drugs & Pharmaceuticals Inc Share Price Chart — NSE/BSE Historical Performance
Venmax Drugs & Pharmaceuticals Inc share price chart: -12.91% return over the past month. 52-week high ₹36.96, 52-week low ₹19.01.
Venmax Drugs & Pharmaceuticals Inc — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹24.99 | ₹24.99 | ₹19.26 | ₹21.18 | 5.36K (Cr) | |
| ₹24.00 | ₹24.00 | ₹22.00 | ₹22.94 | 454.00 (Cr) | |
| ₹24.61 | ₹26.88 | ₹24.00 | ₹24.00 | 456.00 (Cr) | |
| ₹26.99 | ₹26.99 | ₹23.00 | ₹24.86 | 3.02K (Cr) | |
| ₹23.89 | ₹24.96 | ₹23.00 | ₹23.18 | 1.41K (Cr) | |
| ₹24.00 | ₹24.00 | ₹22.60 | ₹23.89 | 1.95K (Cr) | |
| ₹24.99 | ₹24.99 | ₹23.96 | ₹24.00 | 295.00 (Cr) | |
| ₹23.21 | ₹24.90 | ₹22.27 | ₹23.96 | 348.00 (Cr) | |
| ₹24.99 | ₹24.99 | ₹22.61 | ₹23.21 | 1.76K (Cr) | |
| ₹24.00 | ₹25.40 | ₹23.02 | ₹23.36 | 444.00 (Cr) |
Venmax Drugs & Pharmaceuticals Inc — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹24.00 | ₹24.99 | ₹19.26 | ₹21.18 | -11.75% | |
| ₹24.55 | ₹26.99 | ₹22.27 | ₹24.00 | -2.24% | |
| ₹26.00 | ₹30.00 | ₹22.01 | ₹24.51 | -5.73% | |
| ₹27.40 | ₹27.55 | ₹20.80 | ₹25.77 | -5.95% | |
| ₹23.56 | ₹30.17 | ₹22.39 | ₹25.39 | +7.77% | |
| ₹24.70 | ₹28.07 | ₹22.71 | ₹24.73 | +0.12% | |
| ₹30.49 | ₹31.49 | ₹23.42 | ₹24.95 | -18.17% | |
| ₹28.00 | ₹31.45 | ₹25.92 | ₹29.04 | +3.71% | |
| ₹20.10 | ₹31.17 | ₹19.01 | ₹28.00 | +39.30% | |
| ₹30.30 | ₹30.30 | ₹21.05 | ₹21.15 | -30.20% | |
| ₹25.20 | ₹36.96 | ₹23.93 | ₹31.89 | +26.55% | |
| ₹25.03 | ₹30.68 | ₹22.50 | ₹26.47 | +5.75% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Micro-cap pharma turnaround story with high execution risk and liquidity concerns; avoid unless you're a gambler.
WHAT'S HAPPENING NOW
Venmax Drugs appointed Mrs. Padmaja Kalyani Sadhanala as an Additional Director effective March 30, 2026. They also amended the Hatri Pharma merger plan, revising the share capital. Mr. Venkata Rao Sadhanala was appointed as Managing Director for 5 years starting March 11, 2026.
CORE STORY
Venmax is a micro-cap pharma company attempting a turnaround through mergers and management changes. The market is likely viewing this as a high-risk, high-reward play dependent on successful execution of the Hatri Pharma merger and the new MD's strategy.
- Merger amendment
- New MD appointment
- Sector export growth
- Successful merger integration
- New product launches
- Significant order wins
- Micro-cap liquidity risk
- Integration challenges with Hatri Pharma
- Execution risk with new management
No FII/DII activity. Promoter holding steady at 23.13% [cite: brief].
Indian pharma exports growing, but US tariff concerns linger.
No. Negative free cash flow of ₹-0.12 Cr over the last 5 years [cite: brief].
Next 3-6 months hinge on the Hatri Pharma merger progress and initial strategy announcements from the new MD. Expect volatility.
Primary Thesis Risk
Failure to successfully integrate Hatri Pharma will crater the stock.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Venmax Drugs & Pharmaceuticals Inc Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Venmax Drugs & Pharmaceuticals Inc Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VENMAX across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Robust Profit Growth (106.67%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (676.47%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (19.57% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (19.57% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (6.38%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (5.29%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 45.94x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Negative Free Cash Flow (₹-0.12 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (23.13%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Venmax Drugs & Pharmaceuticals Inc vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Venmax Drugs & Pharmaceuticals Inc with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
41.1/100 | ₹21.18₹21 | ₹15.62₹15.62 | 45.94Average 45.9 Average | 6.38%Poor 6.38% Poor | 5.29%Poor 5.29% Poor | 0.36Excellent 0.4 Excellent | 19.57%Excellent 19.57% Excellent | 11.50%Good 11.50% Good | 0.00% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1782.20₹1782 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6623.00₹6623 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4420.90₹4421 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1401.30₹1401 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1278.20₹1278 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2267.70₹2268 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹1089.00₹1089 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2336.10₹2336 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1462.30₹1462 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5251.50₹5252 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Venmax Drugs & Pharmaceuticals Inc Quarterly Performance
Latest quarterly metrics for VENMAX — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
676.47%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
106.67%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
11.50%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
19.57%
Compounded annual net profit growth over 5 years
Venmax Drugs & Pharmaceuticals Inc Technical Indicators
SMA 50, SMA 200, RSI and volume signals for VENMAX — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Venmax Drugs & Pharmaceuticals Inc Financial Statements
Annual income statement, balance sheet and cash flow for Venmax Drugs & Pharmaceuticals Inc (VENMAX) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Venmax Drugs & Pharmaceuticals Inc
About VENMAX (Venmax Drugs & Pharmaceuticals Inc)
Venmax Drugs & Pharmaceuticals Inc. is a biopharmaceutical company committed to the discovery, development, and commercialization of innovative therapies that address unmet medical... needs. With a focus on enhancing patient outcomes and improving quality of life, VENMAX leverages cutting-edge science and a dedication to rigorous research to bring transformative medications to market. Headquartered in Hyderabad, India, the company operates a state-of-the-art research and manufacturing facility, adhering to the highest international standards of quality and safety. VENMAX is driven by a team of experienced scientists, clinicians, and business professionals, united by a shared passion for advancing healthcare and making a positive impact on global health. The core of VENMAX's business lies in its diverse portfolio of pharmaceutical products, encompassing a range of therapeutic areas. From generics to innovative formulations, the company caters to various healthcare needs with a constant push for affordable and accessible medicines. VENMAX actively pursues strategic collaborations and partnerships to expand its product offerings and geographical reach, ensuring its therapies are available to patients worldwide. Committed to ethical practices and sustainability, the company strives to minimize its environmental footprint and contribute to the well-being of the communities in which it operates. VENMAX's commitment to innovation extends beyond its product pipeline. The company invests heavily in research and development, exploring novel drug delivery systems and personalized medicine approaches. VENMAX aims to pioneer new treatments and improve the lives of patients by staying at the forefront of scientific advancements. Through its dedication to excellence, ethical practices, and collaborative spirit, VENMAX is poised to remain a significant player in the pharmaceutical landscape, making meaningful contributions to the future of healthcare.
Company Details
Key Leadership
Latest News
VENMAX Share Price: Frequently Asked Questions
What is the current share price of Venmax Drugs & Pharmaceuticals Inc?
Venmax Drugs & Pharmaceuticals Inc (VENMAX) trades at ₹21.18 on NSE and BSE. Market cap ₹15.62 (Cr). Educational data only.
What is the P/E ratio of Venmax Drugs & Pharmaceuticals Inc?
Venmax Drugs & Pharmaceuticals Inc has a P/E of 45.94x vs industry average 31.77x.
What is the Bull Run score for Venmax Drugs & Pharmaceuticals Inc?
Venmax Drugs & Pharmaceuticals Inc has a Bull Run score of 41.1/100 based on 25+ financial parameters.
Does Venmax Drugs & Pharmaceuticals Inc pay dividends?
Venmax Drugs & Pharmaceuticals Inc has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Venmax Drugs & Pharmaceuticals Inc?
Venmax Drugs & Pharmaceuticals Inc has ROE of 6.38%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Venmax Drugs & Pharmaceuticals Inc?
Venmax Drugs & Pharmaceuticals Inc has debt-to-equity of 0.36.
Is Venmax Drugs & Pharmaceuticals Inc a good investment?
Bull Run gives Venmax Drugs & Pharmaceuticals Inc a score of 41.1/100. This is not investment advice — consult a SEBI-registered advisor.